Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer, FDA slated to discuss aspirin professional labeling for cardiovascular uses.

This article was originally published in The Tan Sheet

Executive Summary

ASPIRIN FOR CARDIOVASCULAR USE PROFESSIONAL LABELING potential indications will be discussed at an Aug. 28 OTC "feedback" meeting requested by Bayer. Professional labeling currently includes indications for aspirin use for the reduction of death and/or nonfatal myocardial infarction in patients with previous MI or unstable angina pectoris, and for the reduction of the risk of transient ischemic attack (TIA) in men. The current indications are included in FDA's November 1988 tentative final monograph for OTC internal analgesic, antipyretic and antirheumatic drug products. Aspirin is known to help prevent MI by inhibiting prostaglandin synthesis with blood platelets and retarding platelet aggregation.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087444

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel